To validate the protein expression of the risk gene signature, we performed IHC analysis on NCBP2 and EIF4A1 using PRAD pathologic specimens obtained from laparoscopic radical prostatectomy (LRP). The gene discussed is NCBP2; the disease is prostate adenocarcinoma.